Welmoed Van Zuiden
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Welmoed Van Zuiden has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Aviad Siany
Weizmann Institute of Science
2 shared publications Chen Bar
Weizmann Institute of Science
2 shared publications- Eran Hornstein
Department of Molecular Genetics, Weizmann Institute of Science
2 shared publications - Nancy-Sarah Yacovzada
Weizmann Institute of Science
2 shared publications - Thea Meimoun
Nash Family Department of Neuroscience and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA
2 shared publications - Adam N. Trautwig
Center for Neurodegenerative Diseases, Emory University, Atlanta, USA
1 shared publication
Latest Publications
- Open Access
TDP-43 toxic gain of function links ALS, FTD and Alzheimer's disease via mis-splicing
TDP-43 proteinopathy is a hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). It is also common in Alzheimer's disease (AD) and limbic-predominant age-related TDP-43 encephalopathy (LATE), but its functional consequences are unclear. Here, we show that TDP-43 pathology in AD is broadly associated with splicing abnormalities. We define a conserved TDP-43-dependent splicing signature in AD that includes AD-relevant mis-spliced mRNAs such as amyloid precursor protein (APP). TDP-43 drives the formation of elongated APP isoforms across ALS, FTLD-TDP and AD, providing a mechanism for the long-standing observation of APP isoform dysregulation. APP isoform imbalance correlates with and partially mediates the association between TDP-43 pathology and Aβ burden and is spatially associated with pTDP-43 and mis-spliced STMN2 in LATE hippocampus. Contrary to a pure nuclear loss-of-function model, mis-splicing is driven by cytoplasmic TDP-43 gain-of-function that co-sequesters splicing-regulatory RNA-binding proteins. Knockdown of TDP-43-associated RNA-binding proteins recapitulates disease-relevant splicing changes in AD and ALS/FTLD-TDP, and some of these proteins colocalize with cytoplasmic pTDP-43 in neuropathological samples. Our findings establish cytoplasmic TDP-43-driven splicing dysfunction as a key component of neurodegeneration, define disease-relevant mis-spliced mRNAs in AD and unite AD with ALS/FTLD-TDP through a shared mechanism of splicing factor sequestration.
Open AccessTDP-43 toxic gain of function links ALS, FTD and Alzheimer's disease via mis-splicing
TDP-43 proteinopathy is a hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). It is also common in Alzheimer's disease (AD) and limbic-predominant age-related TDP-43 encephalopathy (LATE), but its functional consequences are unclear. Here, we show that TDP-43 pathology in AD is broadly associated with splicing abnormalities. We define a conserved TDP-43-dependent splicing signature in AD that includes AD-relevant mis-spliced mRNAs such as amyloid precursor protein (APP). TDP-43 drives the formation of elongated APP isoforms across ALS, FTLD-TDP and AD, providing a mechanism for the long-standing observation of APP isoform dysregulation. APP isoform imbalance correlates with and partially mediates the association between TDP-43 pathology and Aβ burden and is spatially associated with pTDP-43 and mis-spliced STMN2 in LATE hippocampus. Contrary to a pure nuclear loss-of-function model, mis-splicing is driven by cytoplasmic TDP-43 gain-of-function that co-sequesters splicing-regulatory RNA-binding proteins. Knockdown of TDP-43-associated RNA-binding proteins recapitulates disease-relevant splicing changes in AD and ALS/FTLD-TDP, and some of these proteins colocalize with cytoplasmic pTDP-43 in neuropathological samples. Our findings establish cytoplasmic TDP-43-driven splicing dysfunction as a key component of neurodegeneration, define disease-relevant mis-spliced mRNAs in AD and unite AD with ALS/FTLD-TDP through a shared mechanism of splicing factor sequestration.
- Open Access
Organellomics: AI-driven deep organellar phenotyping reveals novel ALS mechanisms in human neurons
Systematic assessment of organelle architectures, termed the organellome , offers valuable insights into cellular states and pathomechanisms, but remains largely uncharted. Here, we present a deep phenotypic learning based on vision transformers, resulting in the Neuronal Organellomics Vision Atlas (NOVA) model that studies confocal images of more than 30 markers of distinct membrane-bound and membraneless organelles in 11.5 million images of human neurons. Organellomics analysis quantifies perturbation-induced changes in organelle localization and morphology using a rigorous mixed-effects meta-analytic framework that accounts for sampling variance and experimental heterogeneity. Applying this approach, we delineate phenotypic alterations in neurons carrying ALS-associated mutations and uncover a physical and functional crosstalk between cytoplasmic mislocalized TDP-43, a hallmark of ALS, and processing bodies (P-bodies), membraneless organelles regulating mRNA stability. These findings are validated in patient-derived neurons and human neuropathology. NOVA establishes a scalable framework for quantitative mapping of subcellular phenotypes and provides a new avenue for investigating the neurocellular basis of disease.
Open AccessOrganellomics: AI-driven deep organellar phenotyping reveals novel ALS mechanisms in human neurons
Systematic assessment of organelle architectures, termed the organellome , offers valuable insights into cellular states and pathomechanisms, but remains largely uncharted. Here, we present a deep phenotypic learning based on vision transformers, resulting in the Neuronal Organellomics Vision Atlas (NOVA) model that studies confocal images of more than 30 markers of distinct membrane-bound and membraneless organelles in 11.5 million images of human neurons. Organellomics analysis quantifies perturbation-induced changes in organelle localization and morphology using a rigorous mixed-effects meta-analytic framework that accounts for sampling variance and experimental heterogeneity. Applying this approach, we delineate phenotypic alterations in neurons carrying ALS-associated mutations and uncover a physical and functional crosstalk between cytoplasmic mislocalized TDP-43, a hallmark of ALS, and processing bodies (P-bodies), membraneless organelles regulating mRNA stability. These findings are validated in patient-derived neurons and human neuropathology. NOVA establishes a scalable framework for quantitative mapping of subcellular phenotypes and provides a new avenue for investigating the neurocellular basis of disease.